Abstract
Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumor. Studies have demonstrated that the toll‑like receptor 3 (TLR3)/interferon pathway is inhibitory in cancer cell proliferation, suggesting that the activation of this pathway may have therapeutic potential. In the present study, the inhibitory effects of BM‑06, a double‑stranded (ds)RNA TLR3 agonist, against HCC were studied in vivo. Using a 2‑acetylaminofluorene-induced HCC rat model, histological examination and analysis of corresponding biomarkers following treatment with BM-06, showed a decrease in tumor growth and cell proliferation, and an increase in apoptosis compared with that in a phosphate‑buffered saline control group. In addition, the observed antitumor effect of BM‑06 in the HCC rat model was demonstrated to be superior to the known TLR3 agonist, polyinosinic-polycytidylic acid.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Apoptosis / drug effects
-
Caspase 8 / genetics
-
Caspase 8 / metabolism
-
Cell Proliferation
-
Drug Screening Assays, Antitumor
-
Gene Expression
-
Interferon-gamma / genetics
-
Interferon-gamma / metabolism
-
Liver / pathology
-
Liver Neoplasms, Experimental / drug therapy*
-
Liver Neoplasms, Experimental / pathology
-
Male
-
NF-kappa B / genetics
-
NF-kappa B / metabolism
-
RNA, Double-Stranded / pharmacology*
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Rats
-
Rats, Sprague-Dawley
-
Toll-Like Receptor 3 / agonists
-
Tumor Burden / drug effects
-
Vascular Endothelial Growth Factor A / genetics
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Antineoplastic Agents
-
BM-06
-
NF-kappa B
-
RNA, Double-Stranded
-
RNA, Messenger
-
TLR3 protein, rat
-
Toll-Like Receptor 3
-
Vascular Endothelial Growth Factor A
-
vascular endothelial growth factor A, rat
-
Interferon-gamma
-
Casp8 protein, rat
-
Caspase 8